Addex Therapeutics, Janssen Gets FDA Approval to Begin Proof of Concept Study
By Chris Wack
Addex Therapeutics Ltd. said its partner, Janssen
Pharmaceuticals Inc., has received the U.S. Food and Drug
Administration's Investigational New Drug approval to begin a Phase
2a proof of concept study for a treatment for patients with
The clinical-stage pharmaceutical company said the first patient
is expected to be treated during the second quarter of 2021.
Addex said the multi-center study will assess the efficacy,
safety, tolerability and pharmacokinetics of adjunctive
JNJ-40411813 administration in patients with focal onset seizures
with suboptimal response to levetiracetam.
The primary objective of the study is to evaluate the efficacy
of JNJ-40411813 in combination with levetiracetam using a
Addex Therapeutics shares were up 65% to $17.79 in premarket
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
January 21, 2021 06:28 ET (11:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.